Press Release for Q1 FY 2026-27

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 August 11, 2026 BSE Limited N ational Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Symbol: VIYASH Dear Sir/ Madam, Subject: Press Release for Q1 FY 2026-27 Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Press Release on Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. This is for your information and appropriate dissemination. Thanking you, Yours faithfully, For Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000, E:info@viyash.com E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 Marching ahead on the integrated platform journey with robust growth Q1 FY27 Performance Highlights • Revenues at ₹ 9,464 Million up by 19.5% • EBITDA* at ₹ 2,047 Million up 59.2 % • PAT at ₹ 793 Million, up by 114.9% • Net Debt / EBITDA* at 0.1 x Hyderabad, August 11, 2026 Viyash Scientific Limited (formerly SeQuent Scientific Limited), which has businesses spread across Formulations, APIs and CDMO Services for Human and Animal health, today announced its financial results for the quarter ended June 30, 2026. Consolidated Financial Highlights ₹ in millions Q1FY27 Q1FY26 Growth % Revenues 9,464 7,916 19.5% EBITDA* 2,047 1,286 59.2% EBITDA* % 21.6% 16.2% PAT 793 369 114.9% EBITDA* refers to EBITDA excluding ESOP costs Detailed presentation on the performance forms part of this press release Commenting on the Company’s performance, Dr Hari Babu Bodepudi, Managing Director and Group CEO stated that “Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth " Earnings Call with Investors The Company will conduct an Earnings call at 3:30 PM IST on August 12, 2026 where the Management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are +91 22 6280 1263 or +91 22 7115 8213 About Viyash Scientific Limited Viyash Scientific Limited (formerly known as Sequent Scientific Limited) headquartered in India is globally among top-25 Animal Health companies. With over 3,000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in 100+ countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. For details, feel free to contact Yoshita Vora Registered Office Company Secretary, Tel: +91 22 4111 4717 3rd Floor, Srivalli’s Corporate, investorrelations@viyash.com Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana Abhishek Singhal CIN: L99999TS1985PLC196357 Investor Relations Consultants BSE Code: 512529 I NSE: VIYASH abhishek@arunya.co.in ISIN: INE807F01027 I REUTERS: EQU.BO Website: www.viyash.com Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Viyash Scientific Ltd. will not be responsible in any way for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstance.